The FDA has approved new options for the treatment of melanoma lesions, soft tissue sarcomas, and the rare metabolic disease, hypophosphatasia, that clinicians should be aware of.
In a breakthrough clinical trial, researchers tested a genetically engineered version of the herpes simplex virus designed to combat melanoma by multiplying inside cancer cells and killing them.
